Latest Press Releases

To help improve access to fast, reliable testing for veterans, Walgreens is now offering no-cost testing through a partnership with the Centers for Disease Control and Prevention (CDC).* Eligible veterans will be able to receive an easy combination test for COVID-19 and influenza at Walgreens locations across the country throughout this year’s respiratory season, with results in 30 minutes or less.** No-cost COVID-19 and flu testing will also continue to be available at Walgreens for uninsured patients via the CDC program.

DermaSensor, a world leader in skin cancer diagnostic technology, announced the company’s inclusion in TIME’s Best Inventions of 2024 list under the Medical Care category. TIME’s prestigious award recognizes 200 innovations that TIME editors deem as the most impactful new products and ideas globally.

Shorla Oncology a U.S.-Ireland specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has expanded the approval of JYLAMVO™ (methotrexate) to include the treatment of pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA). With this approval, JYLAMVO is currently the only oral liquid methotrexate on the market approved for both adult and pediatric indications.

Advanced NanoTherapies (ANT), a clinical-stage medical device company committed to solving the most significant challenges in vascular disease through innovative applications of nanotechnology, announced positive results from its first-in-human (FIH) trial evaluating the next-generation SirPlux™ Duo Drug-Coated Balloon (DCB).

Bora Pharmaceuticals Co., Ltd. announced that its Board of Directors has approved the acquisition of US-based Pyros Pharmaceuticals, Inc. ("Pyros"), a specialty pharmaceutical company developing treatments for rare diseases.

Anixa Biosciences, Inc. "Anixa" or the a biotechnology company focused on the treatment and prevention of cancer, announced that it has administered the second dose of its CAR-T therapy to an individual patient.This follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted in collaboration with Moffitt Cancer Center.

Regenity Biosciences, a global leader in regenerative medicine and Linden Capital Partners portfolio company, announced that it has received FDA 510(k) clearance to market RejuvaKnee™, a minimally invasive collagen-based meniscal implant indicated for use in the reinforcement and repair of soft tissue injuries of the meniscus.

BioIntelliSense, a continuous health monitoring and clinical intelligence company, announces FDA clearance of the rechargeable BioButton® Multi-Patient wearable and BioDashboard™ system to cost-effectively grow and scale hospital virtual care programs.

Emulate, Inc., the leading provider of next-generation in vitro Organ-Chip models, announced the release of its new Chip-R1™ Rigid Chip, designed to minimize drug absorption and enhance biological modeling. Constructed using low-drug-absorbing plastics, Chip-R1 builds upon the core microfluidic design of Organ-Chips, offering researchers greater precision in predicting human drug responses.

Spineology Inc., the pioneer of Conform and Expand™ Technology, unveiled a new brand and visual identity, logo, and product positioning as part of an extensive rebranding initiative. This new brand defines Spineology’s flagship interbody fusion portfolio, OptiMesh®, and establishes it within a category of its own.